February 2026 in “Bioengineering” Platelet-rich plasma treatment is more effective than pelvic floor muscle training for improving quality of life in women with stress urinary incontinence.
January 2026 in “Journal of Radiation Research” 53BP1 focus analysis in hair cells can help estimate radiation doses.
January 2026 in “SKIN The Journal of Cutaneous Medicine” Androgenetic alopecia patients often experience higher rates of depression and anxiety, suggesting mental health screening before finasteride treatment.
January 2026 in “Journal of Crohn s and Colitis” High-dose IV iron is safe and effective for treating anaemia in IBD patients.
Virtual healthcare significantly improves quality of life for men with hair loss if they stick to the treatment.
November 2025 in “Anxiety Stress & Coping” Higher anxiety symptoms and social behavior affect stress levels in hair.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
November 2025 in “Fayoum University Medical Journal/Fayoum University Medical Journal ” Intralesional vitamin D3 injections can improve vitamin D3 levels and may help treat alopecia areata.
November 2025 in “Asian Journal of Medical Sciences” Early menarche may indicate higher risk of severe hirsutism in PCOS patients.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
September 2025 in “PubMed” Thulium laser therapy is a safe and effective short-term treatment for hair regrowth in androgenic alopecia patients.
August 2025 in “Journal of Cosmetic Dermatology” Oral minoxidil users, especially for hypertension, may risk heart issues, and better monitoring guidelines are needed for alopecia patients.
July 2025 in “Journal of Investigative Dermatology” Spironolactone can safely lower blood pressure in patients on other blood pressure medications, but may slightly increase the risk of low blood pressure.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
The study aims to find the best PRP dose for treating moderate carpal tunnel syndrome.
July 2025 in “Dermatologic Surgery” PRP may increase hair density but doesn't improve quality of life in breast cancer survivors with hair loss.
June 2025 in “British Journal of Dermatology” Low-dose oral minoxidil is increasingly used by dermatologists in the UK and Ireland to treat various hair loss conditions.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
May 2025 in “Health Science Reports” Serum WS Biotin significantly reduces hair shedding and improves hair thickness.
Bempikibart may help regrow hair in people with alopecia areata.
Survivors of severe COVID-19 need ongoing care to manage lasting health issues.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
January 2025 in “Heliyon” Tamsulosin and finasteride have similar effects on blood sugar control in men with type 2 diabetes.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.